Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: A report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project Academic Article uri icon

Overview

MeSH Major

  • Immunoconjugates
  • Leukoencephalopathy, Progressive Multifocal

abstract

  • PML can develop after a few BV doses and within weeks of BV initiation. Clinicians should be aware of this syndrome, particularly when neurologic changes develop after the initiation of BV treatment. The decision to administer BV to patients with indolent cutaneous lymphomas should be based on consideration of risk-benefit profiles and of alternative options.

publication date

  • August 15, 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4460831

Digital Object Identifier (DOI)

  • 10.1002/cncr.28712

PubMed ID

  • 24771533

Additional Document Info

start page

  • 2464

end page

  • 71

volume

  • 120

number

  • 16